NCT02631746 2025-03-14Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaNational Cancer Institute (NCI)Phase 2 Completed3 enrolled 8 charts
NCT03075553 2020-04-21Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaMayo ClinicPhase 2 Terminated12 enrolled 13 charts